Transparency at HHS: How the New “Radical Transparency” Initiative Aims to Expose Big Pharma Conflicts

In Brief: HHS “Transparency” Under Scrutiny

When Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. promised an era of “radical transparency” in early 2025, it was met with cautious optimism. However, a series of actions in the months since have raised serious alarms among public health advocates and government watchdogs. Instead of opening doors, the new administration appears to be systematically closing them, shielding one of the government’s largest departments from public view.

• Promise vs. Reality: The initial pledge to make HHS data and policies fully transparent has been directly contradicted by recent moves.
• Committees Under Fire: An executive order has labeled the nearly 1,000 federal advisory committees—a key source of public insight into agencies like the FDA—as “unnecessary” and marked them for potential elimination.
• Public Input Silenced: Critical public health meetings have been canceled without clear reason, and a new policy aims to remove public comment periods for most HHS operations, citing cost and inefficiency.
• Growing Backlash: Patient advocacy groups are actively protesting these changes, arguing that public oversight is essential for accountability, especially within an agency that spends over $2 trillion in taxpayer funds annually.

The Promise of Radical Transparency at HHS: A New Era?

When Robert F. Kennedy Jr. took the helm of U.S. Health and Human Services (HHS) on February 13, 2025, his declaration of “radical transparency” sent a wave of hope through the health and wellness community. “We will make our data and our policy process so transparent that people won’t even have to file a FOIA [Freedom of Information Act] request,” Kennedy announced. For many, it signaled a potential shift away from the opaque processes that have long fueled public distrust.

Having served on the FDA’s Drug Safety and Risk Management Advisory Committee from 2017 to 2024, I witnessed firsthand the systemic opacity. I saw speakers claim no conflicts of interest while being funded by pharmaceutical-backed groups and watched as crucial post-approval drug studies went unfulfilled without consequence. The pledge to open the doors of the $2.34 trillion department was more than welcome; it was essential to restoring credibility. Yet, within weeks, a series of alarming actions suggested this new transparency was little more than a mirage.

Cracks in the Facade: Early Warning Signs for Public Health Oversight

The initial optimism quickly soured as the administration’s actions began to directly contradict its words. These moves, executed swiftly in the weeks following Kennedy’s appointment, have raised red flags about the future of public accountability in American healthcare. Critics now fear that this promised transparency looks more like a closed door.

Red Flag 1: Dismantling the Watchdogs

On February 19, 2025, just days after the transparency vow, an executive order declared federal advisory committees “unnecessary” and slated them for review and possible elimination. These 1,000 committees were established by Congress to provide independent, expert advice on critical matters. For decades, their public meetings have been the American public’s only consistent window into the decision-making of agencies like the FDA. Without them, processes already shielded from scrutiny will vanish completely into the shadows.

Red Flag 2: The Unexplained Cancellation of Critical Meetings

A day later, the tri-annual Advisory Committee on Immunization Practices (ACIP) meeting was abruptly canceled without explanation. This committee’s work is vital for approving the seasonal flu vaccine in time for manufacturing and distribution. An HHS spokesperson later claimed more time was needed for public comment, a disingenuous justification since the public comment portal for the meeting was never even opened. The move frustrated lawmakers on both sides of the aisle, who had received assurances from Kennedy that he would work within the existing vaccine approval systems.

The Final Blow: Eliminating Public Comment and Sealing the Doors

Perhaps the most direct assault on transparency came when Kennedy moved to eliminate public input altogether. In a policy document posted to the federal register, his department stated that public comment periods “impose costs on the Department and the public, are contrary to the efficient operation of the Department, and impede the Department’s flexibility.” This claim that listening to the public is too costly for an agency that spends $2 billion a day is staggering. The move to reduce oversight was itself implemented without any opportunity for public comment, an irony that has not been lost on critics. These administrative changes that decrease transparency at HHS undermine the very foundation of public accountability.

In an era where health misinformation on social media is rampant, reducing official transparency only creates a larger vacuum for falsehoods to fill. It stands in stark contrast to other federal pushes, such as the new law requiring hospitals to post their prices, which aim for greater clarity for consumers. As nearly two dozen patient advocacy groups have argued in a formal request to HHS, public participation is not an obstacle; it is a cornerstone of responsible governance.

• Targeting Advisory Committees: An executive order marked roughly 1,000 expert advisory panels for potential elimination.
• Canceling Key Meetings: The Advisory Committee on Immunization Practices (ACIP) meeting was canceled, jeopardizing timely vaccine decisions.
• Eliminating Public Input: HHS formally moved to end public comment periods on most of its rulemaking, citing cost and inefficiency.
• Contradicting Promises: These actions directly oppose the initial pledge for an era of “radical transparency” and accountability.

The illustration photo accompanying this article was generated by an artificial intelligence model. Fictional testimonials may have been added to illustrate the article’s points.

What was ‘radical transparency’ supposed to mean for HHS?

As initially promised by HHS Secretary Kennedy, ‘radical transparency’ was a pledge to make the department’s data, research, and policymaking processes so open and accessible that formal public information requests would become unnecessary. The stated goal was to rebuild public trust in key health institutions like the FDA and CDC.

Why are federal advisory committees so important for health transparency?

These committees are comprised of independent, external experts who provide scientific and policy advice to agencies like the FDA. Their meetings are held in public, offering the only consistent opportunity for citizens, journalists, and other experts to observe and understand the decision-making process behind drug approvals and major health policies.

What was the immediate impact of canceling the ACIP meeting?

The cancellation of the Advisory Committee on Immunization Practices (ACIP) meeting delayed crucial scientific discussions and decisions regarding the composition of the next season’s influenza vaccine. This created uncertainty and potential delays for manufacturers and public health officials responsible for vaccine distribution.

How did HHS justify its decision to eliminate public comment periods?

In a notice published in the federal register, the Department of Health and Human Services argued that public comment periods ‘impose costs’ and hinder the agency’s ‘flexibility to adapt quickly.’ Critics have dismissed this justification, pointing to the department’s multi-trillion-dollar budget and the fundamental importance of public participation in a democratic society.